Edition:
United Kingdom

Mirati Therapeutics Inc (MRTX.OQ)

MRTX.OQ on NASDAQ Stock Exchange Capital Market

24.80USD
17 Jan 2018
Change (% chg)

$0.55 (+2.27%)
Prev Close
$24.25
Open
$24.30
Day's High
$24.90
Day's Low
$23.50
Volume
188,079
Avg. Vol
208,839
52-wk High
$27.80
52-wk Low
$2.70

Latest Key Developments (Source: Significant Developments)

Beigene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Beigene Ltd ::BEIGENE AND MIRATI THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR SITRAVATINIB IN THE ASIA PACIFIC REGION.BEIGENE LTD - MIRATI WILL RETAIN EXCLUSIVE RIGHTS FOR DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF SITRAVATINIB FOR REST OF WORLD..BEIGENE LTD - UNDER AGREEMENT MIRATI WILL RECEIVE AN UPFRONT CASH PAYMENT OF $10 MILLION FROM BEIGENE.BEIGENE - MIRATI ELIGIBLE TO RECEIVE UP TO $123 MILLION OF EXTRA PAYMENTS UPON CERTAIN DEVELOPMENT, REGULATORY AND SALES MILESTONES, AMONG OTHERS.BEIGENE - CO, MIRATI THERAPEUTICS ENTERED AGREEMENT FOR DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION OF MIRATI'S SITRAVATINIB IN ASIA.  Full Article

Mirati prices public offering of 2 mln shares at $13 per share​
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Mirati Therapeutics Inc -:Mirati Therapeutics announces pricing of public offering of common stock.Mirati Therapeutics Inc - ‍pricing of underwritten public offering of 2 million shares of its common stock at a price to public of $13.00 per share​.  Full Article

Mirati announces advancement of opportunities with inhibitor programs
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Mirati Therapeutics Inc ::Mirati Therapeutics announces advancement of first-in-class opportunities with sitravatinib and kras inhibitor programs.Mirati Therapeutics - ‍"reprioritizing" development programs to capitalize on data and development opportunities in its sitravatinib and kras programs​.Mirati Therapeutics - ‍reallocation of resources to support expansion of sitravatinib and kras programs, is expected to fund operations into late 2019​.  Full Article

Mirati Therapeutics reports Q3 loss per share of $0.65
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Mirati Therapeutics Inc :Mirati Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.65.Q3 earnings per share view $-0.82 -- Thomson Reuters I/B/E/S.‍Research and development expenses for Q3 of 2017 were $13.5 million, compared to $16.1 million for same period in 2016​.  Full Article

Mirati Therapeutics' says drug included in Stand Up To Cancer's clinical trial initiative for NSCLC patients
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Mirati Therapeutics Inc :Mirati Therapeutics' mocetinostat included in stand up to cancer's cutting-edge clinical trial initiative for NSCLC patients.  Full Article

Broadfin Capital, LLC reports 5.02 pct passive stake in Mirati Therapeutics
Wednesday, 10 Aug 2016 

Mirati Therapeutics Inc : Broadfin Capital, LLC reports 5.02 pct passive stake in Mirati Therapeutics as of August 8, 2016 - SEC Filing Source - http://bit.ly/2aMdcIv Further company coverage: [MRTX.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Mirati Therapeutics reports Q2 loss per share of $1.11
Thursday, 4 Aug 2016 

Mirati Therapeutics Inc : Q2 loss per share $1.11 . Mirati therapeutics reports financial results and provides business update for the second quarter 2016 .Q2 earnings per share view $-1.15 -- Thomson Reuters I/B/E/S.  Full Article

Mirati Therapeutics, Inc announces leadership changes
Wednesday, 23 Mar 2016 

Mirati Therapeutics, Inc:Says promotion of Jamie A. Donadio to Senior Vice President and Chief Financial Officer, effective as of March 21, 2016.  Full Article

BRIEF-Beigene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region

* BEIGENE AND MIRATI THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR SITRAVATINIB IN THE ASIA PACIFIC REGION